Maxim Kobelev
Overview
Explore the profile of Maxim Kobelev including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nouruzi S, Namekawa T, Tabrizian N, Kobelev M, Sivak O, Scurll J, et al.
JCI Insight
. 2024 Oct;
9(23).
PMID: 39470735
Lineage plasticity mediates resistance to androgen receptor pathway inhibitors (ARPIs) and progression from adenocarcinoma to neuroendocrine prostate cancer (NEPC), a highly aggressive and poorly understood subtype. Neuronal transcription factor ASCL1...
2.
Tabrizian N, Nouruzi S, Cui C, Kobelev M, Namekawa T, Lodhia I, et al.
Cell Rep
. 2023 Aug;
42(8):112937.
PMID: 37552603
Lineage plasticity is a form of therapy-induced drug resistance. In prostate cancer, androgen receptor (AR) pathway inhibitors potentially lead to the accretion of tumor relapse with loss of AR signaling...
3.
Nouruzi S, Ganguli D, Tabrizian N, Kobelev M, Sivak O, Namekawa T, et al.
Nat Commun
. 2022 Apr;
13(1):2282.
PMID: 35477723
Treatment with androgen receptor pathway inhibitors (ARPIs) in prostate cancer leads to the emergence of resistant tumors characterized by lineage plasticity and differentiation toward neuroendocrine lineage. Here, we find that...
4.
Singh N, Ramnarine V, Song J, Pandey R, Padi S, Nouri M, et al.
Nat Commun
. 2021 Dec;
12(1):7349.
PMID: 34934057
Neuroendocrine (NE) prostate cancer (NEPC) is a lethal subtype of castration-resistant prostate cancer (PCa) arising either de novo or from transdifferentiated prostate adenocarcinoma following androgen deprivation therapy (ADT). Extensive computational...
5.
Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, et al.
Nat Cell Biol
. 2021 Sep;
23(9):1023-1034.
PMID: 34489572
Cancers adapt to increasingly potent targeted therapies by reprogramming their phenotype. Here we investigated such a phenomenon in prostate cancer, in which tumours can escape epithelial lineage confinement and transition...
6.
Ramnarine V, Kobelev M, Gibb E, Nouri M, Lin D, Wang Y, et al.
Eur Urol
. 2019 Aug;
76(5):546-559.
PMID: 31445843
Context: It is increasingly evident that non-protein-coding regions of the genome can give rise to transcripts that form functional layers of the cancer genome. One of most abundant classes in...
7.
Ramnarine V, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, et al.
Gigascience
. 2018 May;
7(6).
PMID: 29757368
Background: Treatment-induced neuroendocrine prostate cancer (tNEPC) is an aggressive variant of late-stage metastatic castrate-resistant prostate cancer that commonly arises through neuroendocrine transdifferentiation (NEtD). Treatment options are limited, ineffective, and, for...